Answers are grounded in this paper and cite their sources.
Drugs that block angiogenesis are important components of first-line therapies for a number of human cancers. However, some of these agents have undesirable effects on the patient. Optimal delivery systems must be developed to maximize clinical benefits and minimize adverse effects in cancer patients. In this Perspective, we discuss these drug-related issues and propose ways to optimize antiangiogenic therapy by the development of new drug delivery systems.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: